News
MEDP
676.77
+1.13%
7.58
Medpace Holdings Price Target Raised to $670.00/Share From $600.00 by BMO Capital
Dow Jones · 11h ago
Medpace Holdings Is Maintained at Market Perform by BMO Capital
Dow Jones · 11h ago
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $670
Benzinga · 11h ago
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
NASDAQ · 13h ago
Medpace price target raised to $670 from $600 at BMO Capital
TipRanks · 16h ago
Here's Why Medpace (MEDP) is a Strong Growth Stock
NASDAQ · 16h ago
Weekly Report: what happened at MEDP last week (1019-1023)?
Weekly Report · 19h ago
Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate
Seeking Alpha · 1d ago
Is Medpace Holdings (MEDP) Fully Valued After Its Q3 Earnings Beat?
Simply Wall St · 2d ago
Does $1b Buyback Change The Bull Case For Medpace Shares?
Simply Wall St · 3d ago
Medpace Holdings Inc. Signals Strong Growth in Earnings Call
TipRanks · 3d ago
Medpace Holdings Is Maintained at Neutral by UBS
Dow Jones · 3d ago
Medpace Holdings Price Target Raised to $700.00/Share From $673.00 by UBS
Dow Jones · 3d ago
UBS Maintains Neutral on Medpace Holdings, Raises Price Target to $700
Benzinga · 3d ago
Medpace Holdings Price Target Raised to $633.00/Share From $609.00 by Truist Securities
Dow Jones · 3d ago
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $633
Benzinga · 3d ago
Medpace Holdings Is Maintained at Equal-Weight by Barclays
Dow Jones · 3d ago
Medpace Holdings Price Target Raised to $675.00/Share From $625.00 by Barclays
Dow Jones · 3d ago
Medpace Holdings Is Maintained at Hold by TD Cowen
Dow Jones · 3d ago
Medpace Holdings Price Target Raised to $673.00/Share From $492.00 by TD Cowen
Dow Jones · 3d ago
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.